WO1996017604A1 - Use of a nitric oxide (no) donor for the treatment of hypertension during pregnancy - Google Patents
Use of a nitric oxide (no) donor for the treatment of hypertension during pregnancy Download PDFInfo
- Publication number
- WO1996017604A1 WO1996017604A1 PCT/GB1995/002846 GB9502846W WO9617604A1 WO 1996017604 A1 WO1996017604 A1 WO 1996017604A1 GB 9502846 W GB9502846 W GB 9502846W WO 9617604 A1 WO9617604 A1 WO 9617604A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- donor
- group
- eclampsia
- prophylaxis
- optionally substituted
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 25
- 230000035935 pregnancy Effects 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 27
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 27
- 201000011461 pre-eclampsia Diseases 0.000 claims abstract description 23
- 238000011321 prophylaxis Methods 0.000 claims abstract description 16
- 150000004007 S-nitroso compounds Chemical group 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 150000008575 L-amino acids Chemical class 0.000 claims description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical group [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- -1 salt ester Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000010118 platelet activation Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 201000005608 severe pre-eclampsia Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000036266 weeks of gestation Effects 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004139 eicosanoid metabolism Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000685 uterine artery Anatomy 0.000 description 1
- 230000008346 uterine blood flow Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
Definitions
- the present invention relates to the use of a nitric oxide (NO) donor for the treatment of hypertension during pregnancy, in particular for the treatment of pre-eclampsia.
- NO nitric oxide
- Pre-eclampsia is a multiorgan disease which is unique to human pregnancy.
- the condition is characterised by the development of elevated blood pressure, protein uria, and generalised oedema.
- Pre-eclampsia occurs after 20 weeks of gestation, but most usually after 32 weeks, and accounts for more than 50% of all the hypertensive disorders of pregnancy. It is a major cause of foetal and maternal morbidity and mortality.
- Plasma levels of aldosterone and renin are lower than in normal pregnant individuals but still may be inappropriately high in relation to salt intake and volume status. A decrease in plasma volume and haemoconcentration is typically observed.
- Some have suggested (Internal Medicine, 4th Edition, Part 10, p 2816-2817 (1994)) that this increase in vascular tone is caused by a relative or absolute deficiency in the production of the vasodilating prostaglandin, PGI 2 (prostacyclin). It has also been suggested (Textbook of Medicine, 19th Edition, Vol.
- Pre-eclampsia can be an extremely severe disease and it can be clinically useful to separate the disease into mild and severe cases.
- the criteria frequently used to indicate severe disease is given in Internal Medicine (supra).
- the development of severe pre-eclampsia requires delivery, regardless of gestational age. Even in mild cases of the disease, careful monitoring is required because of the possibility of rapid deterioration.
- a subset of severe pre-ecla ptic patients develop haemolysis (H), elevated liver enzymes (EL), and low platelets (LP), the so-called "HELLP Syndrome". These patients frequently have little blood pressure change and limited symptoms.
- the disease is characterised by rapid deterioration and death if prompt delivery and aggressive supportive therapy are not implemented.
- Present methods of treatment depend on the severity of the condition. For women with mild disease who are remote from term, total bed rest. In cases of severe pre-eclampsia, delivery is generally required, once blood pressure has been controlled.
- the present invention provides the use of a NO donor in the manufacture of a medicament for the prophylaxis and/or control of hypertension during pregnancy.
- a method of prophylaxis and/or control of hypertension during pregnancy comprising administering to a patient in need thereof a therapeutically effective amount of a NO donor.
- NO donor a compound which is capable of liberating NO in the body.
- Hypertensive disorders encountered during pregnancy include pre-eclampsia, eclampsia, chronic hypertension (> 140/90 mm Hg), chronic hypertension with superimposed pre-eclampsia/eclampsia, and late or transient hypertension, in particular the present invention may be used for the prophylaxis and/or treatment of pre-eclampsia.
- the compounds of the present invention may also be used for women suffering from HELLP syndrome and accordingly such use provides a further aspect of the present invention.
- the present invention further provides the use of NO donor in the prophylaxis and/or treatment of pre-eclampsia.
- a method of prophylaxis and/or treatment of pre-eclampsia comprising administering to a patient in need thereof a therapeutically effective amount of an NO donor.
- NO donor any compound which is capable of liberating NO in vivo. Whilst any compound which is a NO donor can be used according to the present invention, a preferred group of compounds are S-nitroso compounds of the formula R-SNO wherein R is one or more amino acid derived fragments.
- the NO donors of the present invention are a group of compounds of formula (I)
- n 0 or 1;
- X is a C ⁇ straight or branched alkylene chain;
- Y and Z may be the same or different and are each a C ⁇ hydrocarbyl chain optionally substituted by one or more groups R 4 and R 5 wherein R 4 and R ⁇ may be the same or different and are selected from hydrogen, C 1-4 alkyl or C ⁇ _ 10 aryl;
- R 1 is hydrogen or a group COR 3 , wherein R 3 CO 2 H is a natural L-amino acid (other than cysteine) and/or the D-isomer thereof;
- R 2 is OH or a group NR 6 R 7 , wherein HNR 6 R 7 is a natural L-amino acid (other than cysteine) and/or the D-isomer thereof;
- the NO donors of the present invention are a group of compounds of formula (IA)
- n, p, q, X, Y and Z are as hereinbefore defined;
- R 1a is hydrogen or a group COR 3a wherein R 3a is a C ⁇ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH 2 ;
- R 2a is OH or a group NR 6a R 7a wherein R 6a is a C ⁇ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH 2 or a C M alkyl group optionally substituted by COOH; and R 7a is hydrogen or a C, ⁇ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH 2 or a C M alkyl group optionally substituted by COOH; or R 6a and R 7a may be joined to form a 5- or 6- membered heterocyclic ring;
- a particularly preferred NO donor for use according to the present invention is S- nitroso-glutathione (GSNO) or all salts, esters and amides thereof.
- GSNO S- nitroso-glutathione
- glyceryl trinitrate may be of use in the prophylactic treatment of pre-eclampsia and other hypertensive conditions.
- the present invention provides a pharmaceutical formulation comprising a NO donor as hereinbefore defined or a pharmaceutically acceptable salt, ester or amide thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients.
- the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intravenous and intraarticular), rectal, vaginal and topical (including dermal, buccal, subfingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a NO donor or a pharmaceutically acceptable salt, ester or amide thereof ("active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, or water-for-injection, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
- Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
- compositions for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
- the effective amount of active ingredient required is from 5 ⁇ g/day to 1mg/day, suitably 50 ⁇ g/day to 500 ⁇ g/day, depending on the particular NO donor administered. Suitably, sufficient compound is given which will liberate 2 ⁇ mol to O. ⁇ mmol of NO/day.
- Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
- the NO donors are suitably administered, orally, by injection (intravenous or subcutaneous), by infusion, or vaginally.
- Platelet activation was assessed by llbllla and p-selectin expression.
- Platelet Activation In 5 out of 6 women, platelet activation was raised before the start of GSNO infusion. In all 5 cases, platelet activation was returned to baseline levels after GSNO infusion.
- Uterine Dopplers Uterine blood flow remained unchanged throughout GSNO infusion in 5 out of the 6 women, however in one there was a dramatic improvement in diastolic flow as assessed by uterine resistance and pulsatility indices.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The use of a NO donor for the prophylaxis and/or treatment of hypertension and hypertensive disorders during pregnancy, in particular for the prophylaxis and/or treatment of pre-eclampsia, is disclosed. Preferably, the NO donor is an S-nitroso compound of the formula R-SNO wherein R is one or more amino acid derived fragments.
Description
USE OF A NITRIC OXIDE (NO) DONOR FOR THE TREATMENT OF HYPERTENSION DURING PREGNANCY
The present invention relates to the use of a nitric oxide (NO) donor for the treatment of hypertension during pregnancy, in particular for the treatment of pre-eclampsia.
Pre-eclampsia is a multiorgan disease which is unique to human pregnancy.
The condition is characterised by the development of elevated blood pressure, protein uria, and generalised oedema. Pre-eclampsia occurs after 20 weeks of gestation, but most usually after 32 weeks, and accounts for more than 50% of all the hypertensive disorders of pregnancy. It is a major cause of foetal and maternal morbidity and mortality.
The cause of pre-eclampsia is not clearly understood. Plasma levels of aldosterone and renin are lower than in normal pregnant individuals but still may be inappropriately high in relation to salt intake and volume status. A decrease in plasma volume and haemoconcentration is typically observed. Some have suggested (Internal Medicine, 4th Edition, Part 10, p 2816-2817 (1994)) that this increase in vascular tone is caused by a relative or absolute deficiency in the production of the vasodilating prostaglandin, PGI2 (prostacyclin). It has also been suggested (Textbook of Medicine, 19th Edition, Vol. 1, p600-601 (1992)) that abnormalities in eicosanoid metabolism may play a role in the pathogenesis of pre-eclampsia, reflecting an imbalance between production of vasodilating prostacyclin and the vasoconstrictor effects of thromboxane.
Pre-eclampsia can be an extremely severe disease and it can be clinically useful to separate the disease into mild and severe cases. The criteria frequently used to indicate severe disease is given in Internal Medicine (supra). In most cases, the development of severe pre-eclampsia requires delivery, regardless of gestational age. Even in mild cases of the disease, careful monitoring is required because of the possibility of rapid deterioration. A subset of severe pre-ecla ptic patients develop haemolysis (H), elevated liver enzymes (EL), and low platelets (LP), the so-called "HELLP Syndrome". These patients frequently have little blood pressure change and limited symptoms. The disease is characterised by rapid deterioration and death if prompt delivery and aggressive supportive therapy are not implemented.
Present methods of treatment depend on the severity of the condition. For women with mild disease who are remote from term, total bed rest. In cases of severe pre-eclampsia, delivery is generally required, once blood pressure has been controlled.
It has been advocated by some that low-dose aspirin (60-80 mg/day) throughout pregnancy for patients at increased risk of developing pre-eclampsia is beneficial. However, in a recent paper (BMJ, 2ΩS, 1250-1251, 14 May 1994), the results of a multicentre trial looking at the use of low dose aspirin in pregnancy were discussed. The theoretical basis of the benefit of aspirin is believed to be its suppression of thromboxane synthesis, which results in less placental aggregation and therefore less placental ischaemia thought to underlie impaired foetal growth and the clinical features of pre-eclampsia. Concern had been expressed about the potential toxicity of such a potent anti-platelet drug for mothers and foetuses. The authors of the paper conclude from the results obtained that there is no justification in the routine prophylaxis or the therapeutic use of antiplatelet treatment in all pregnant women who are at risk of pre- eclampsia. Consequently there is still no really effective means of preventing or controlling pre-eclampsia.
It has now been found that NO donors are of use in the prophylaxis and control of hypertension during pregnancy. Accordingly the present invention provides the use of a NO donor in the manufacture of a medicament for the prophylaxis and/or control of hypertension during pregnancy.
Alternatively there is provided a method of prophylaxis and/or control of hypertension during pregnancy comprising administering to a patient in need thereof a therapeutically effective amount of a NO donor.
By the term NO donor is meant a compound which is capable of liberating NO in the body.
Hypertensive disorders encountered during pregnancy include pre-eclampsia, eclampsia, chronic hypertension (> 140/90 mm Hg), chronic hypertension with superimposed pre-eclampsia/eclampsia, and late or transient hypertension, in particular the present invention may be used for the prophylaxis and/or treatment of pre-eclampsia.
The compounds of the present invention may also be used for women suffering from HELLP syndrome and accordingly such use provides a further aspect of the present invention.
Accordingly the present invention further provides the use of NO donor in the prophylaxis and/or treatment of pre-eclampsia. Alternatively, there is provided a method of prophylaxis and/or treatment of pre-eclampsia comprising administering to a patient in need thereof a therapeutically effective amount of an NO donor.
By the term "NO donor" is meant any compound which is capable of liberating NO in vivo. Whilst any compound which is a NO donor can be used according to the present invention, a preferred group of compounds are S-nitroso compounds of the formula R-SNO wherein R is one or more amino acid derived fragments.
In one aspect, the NO donors of the present invention are a group of compounds of formula (I)
n is 0 or 1; X is a C^ straight or branched alkylene chain;
p and q are independently 0 or 1; Y and Z may be the same or different and are each a C^ hydrocarbyl chain optionally substituted by one or more groups R4 and R5 wherein R4 and Rδ may be the same or different and are selected from hydrogen, C1-4 alkyl or Cβ_10 aryl;
R1 is hydrogen or a group COR3, wherein R3CO2H is a natural L-amino acid (other than cysteine) and/or the D-isomer thereof;
R2 is OH or a group NR6R7, wherein HNR6R7 is a natural L-amino acid (other than cysteine) and/or the D-isomer thereof;
or salts, esters or amides thereof.
In a further aspect, the NO donors of the present invention are a group of compounds of formula (IA)
R1a is hydrogen or a group COR3a wherein R3a is a C^ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2;
R2a is OH or a group NR6aR7a wherein R6a is a C^ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2 or a CM alkyl group optionally substituted by COOH; and R7a is hydrogen or a C,^ hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2 or a CM alkyl group optionally substituted by COOH; or R6a and R7a may be joined to form a 5- or 6- membered heterocyclic ring;
or salts, esters or amides thereof.
A particularly preferred NO donor for use according to the present invention is S- nitroso-glutathione (GSNO) or all salts, esters and amides thereof.
In addition to the above compounds, glyceryl trinitrate may be of use in the prophylactic treatment of pre-eclampsia and other hypertensive conditions.
Whilst it may be possible for the NO donors to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. According to a further aspect, the present invention provides a pharmaceutical formulation comprising a NO donor as hereinbefore defined or a pharmaceutically acceptable salt, ester or amide thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intravenous and intraarticular), rectal, vaginal and topical (including dermal, buccal, subfingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a NO donor or a pharmaceutically acceptable salt, ester or amide thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the
addition of the sterile liquid carrier, for example, saline, or water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
Compositions for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
The effective amount of active ingredient required is from 5 μg/day to 1mg/day, suitably 50μg/day to 500μg/day, depending on the particular NO donor administered. Suitably, sufficient compound is given which will liberate 2μmol to O.δmmol of NO/day. Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
The NO donors are suitably administered, orally, by injection (intravenous or subcutaneous), by infusion, or vaginally.
The present invention will now be described by way of example only:
________
Six women whose pregnancies ranged from 23 to 31 weeks of gestation were studied. All women fulfilled the criteria for pre-eclampsia, namely, proteinuria and hypertension. In addition to this, all babies were growth retarded (abdominal circumference <5th centile for gestation) and all women had high resistance uterine artery perfusion.
All women were already taking maximal oral antihypertensive therapy (methyldopa or nifedipine).
Patients were placed recumbent in a quiet dark room and received a 45 - 90 minute GSNO infusion through a vein in the antecubital fossa. The minimum dose of GSNO used was 50 μg/min, maximum was 250 μg/min. Blood was collected for platelet activation studies through a cannula placed in the opposite antecubital fossa. Blood pressure and pulse was recorded every 10 minutes while the infusion proceeded, and uterine and fetal Doppler waveforms were obtained using an Acuson 128 (Acuson Ltd, Mountainview, CA.) ultrasound machine.
Platelet activation was assessed by llbllla and p-selectin expression.
Results
Blood pressure: All women showed a reduction in arterial blood pressure (Figure 1).
Platelet Activation: In 5 out of 6 women, platelet activation was raised before the start of GSNO infusion. In all 5 cases, platelet activation was returned to baseline levels after GSNO infusion.
Fetal Dopplers: Despite the fall in mean arterial blood pressure, there was no change in the foetal circulation assessed by Doppler ultrasound at any dose of GSNO.
Uterine Dopplers: Uterine blood flow remained unchanged throughout GSNO infusion in 5 out of the 6 women, however in one
there was a dramatic improvement in diastolic flow as assessed by uterine resistance and pulsatility indices.
Claims
1. The use of a NO donor in the manufacture of a medicament for the prophylaxis and/or control of hypertension and/or hypertensive disorders during pregnancy.
2. The use according to claim 1 wherein the hypertensive disorder is pre-eclampsia.
3. The use according to claim 1 wherein the hypertensive disorder is HELLP syndrome.
4. The use of a NO donor in the manufacture of a medicament for the prophylaxis and/or treatment of pre- eclampsia.
5. The use according to any of the preceding claims wherein the NO donor is a S-nitroso compound of the formula R-SNO wherein R is one or more amino acid derived fragments.
6. The use according to any one of the preceding claims wherein the NO donors of the present invention are a group of compounds of formula (I)
wherein
n is 0 or 1; X is a Ci-e straight or branched alkylene chain; p and q are independently 0 or 1; Y and Z may be the same or different and are each a C!-4 hydrocarbyl chain optionally substituted by one or more groups R4 and R5 wherein R4 and R5 may be the same or different and are selected from hydrogen, d-4 alkyl or C6-10 aryl;
R1 is hydrogen or a group COR3, wherein R3C02H is a natural L-amino acid (other than cysteine) and/or the D- isomer thereof;
R2 is OH or a group NR6R7, wherein HNR6R7 is a natural L- amino acid (other than cysteine) and/or the D-isomer thereof;
or a salt, ester or amide thereof.
7. The use according to any one of claims l to 5 wherein the NO donors of the present invention are a group of compounds of formula (IA)
wherein n, p, q, X, Y and Z are as defined in claim 6;
Rla is hydrogen or a group COR3a wherein R3a is a Cj.β hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2;
R2a is OH or a group NR6aR7a wherein R6a is a C_.B hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2 or a d_4 alkyl group optionally substituted by COOH; and R7a is hydrogen or a Ci-β hydrocarbyl group which is optionally substituted by one or two substituents which may be the same or different and are selected from OH, COOH, NH2 or a Cλ.4 alkyl group optionally substituted by COOH; or R6a and R7a may be joined to form a 5- or 6- membered heterocyclic ring;
or a salt, ester or amide thereof.
8. The use according to any preceding claim wherein the NO donor is S-nitroso-glutathione (GSNO) or any salt, ester or amide thereof.
9. The use according to any one of claims 1 to 4 wherein the NO donor is glyceryl trinitrate.
10. A method of prophylaxis and/or controlling hypertension and/or hypertensive disorders during pregnancy comprising administering to a mammal in need thereof an effective amount of a NO donor.
11. A method according to claim 10 wherein the hypertensive disorder is pre-eclampsia.
12. A method according to claim 10 wherein the hypertensive disorder is HELLP syndrome.
13. A method of prophylaxis and/or treatment of pre- eclampsia comprising administering to a mammal in need thereof an effective amount of a NO donor.
14. A method according to any one of claims 10 to 13 wherein the NO donor is a S-nitroso compound of the formula R-SNO wherein R is one or more amino acid derived fragments.
15. A method according to any one of claims 10 to 14 wherein the NO donor is a compound of formula (I) as defined in claim 6.
16. A method according to any one of claims 10 to 14 wherein the NO donor is a compound of formula (la) as defined in claim 7.
17. A method according to any one of claims 10 to 16 wherein the NO donor is S-nitroso-glutathione (GSNO) or any salt ester or amide thereof.
18. A method according to any one of claims 10 to 13 wherein the NO donor is glyceryl trinitrate.
19. A pharmaceutical composition for the prophylaxis and/or control of hypertension and/or hypertensive disorders during pregnancy which comprises a NO donor together with one or more pharmaceutically acceptable carriers thereof.
20. A pharmaceutical composition for the prophylaxis and/or treatment of pre-eclampsia which comprises a NO donor together with one or more pharmaceutically acceptable carriers thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU39910/95A AU3991095A (en) | 1994-12-07 | 1995-12-06 | Use of a nitric oxide (no) donor for the treatment of hypertension during pregnancy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9424694A GB9424694D0 (en) | 1994-12-07 | 1994-12-07 | Compounds for use in medicine |
GB9424694.9 | 1994-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996017604A1 true WO1996017604A1 (en) | 1996-06-13 |
Family
ID=10765553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/002846 WO1996017604A1 (en) | 1994-12-07 | 1995-12-06 | Use of a nitric oxide (no) donor for the treatment of hypertension during pregnancy |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3991095A (en) |
GB (1) | GB9424694D0 (en) |
WO (1) | WO1996017604A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009948A2 (en) * | 1996-09-04 | 1998-03-12 | Nicox S.A. | Nitric ester derivatives and their use in urinary incontinence and other diseases |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US6153186A (en) * | 1995-09-15 | 2000-11-28 | Duke University Medical Center | Red blood cells loaded with S-nitrosothiol and uses therefor |
US6197745B1 (en) | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
WO2002034705A2 (en) * | 2000-10-26 | 2002-05-02 | Duke University | C-nitroso compounds and use thereof |
US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6855691B1 (en) | 1995-09-15 | 2005-02-15 | Duke University | Methods for producing and using S-nitrosohemoglobins |
US6911427B1 (en) | 1995-09-15 | 2005-06-28 | Duke University | No-modified hemoglobins and uses therefore |
US6916471B2 (en) | 1995-09-15 | 2005-07-12 | Duke University | Red blood cells loaded with S-nitrosothiol and uses therefor |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012627A1 (en) * | 1988-06-15 | 1989-12-28 | Brigham And Women's Hospital | S-nitroso derivatives of ace inhibitors and the use thereof |
EP0441119A2 (en) * | 1990-01-09 | 1991-08-14 | Richard D. Levere | The use of L-Arginine in the treatment of hypertension and other vascular disorders |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
WO1995002408A1 (en) * | 1993-07-16 | 1995-01-26 | Schering Aktiengesellschaft | Combination of a progestational agent and a nitric oxide synthase substrate and/or donor for the treatment of preeclampsia and preterm labor |
-
1994
- 1994-12-07 GB GB9424694A patent/GB9424694D0/en active Pending
-
1995
- 1995-12-06 AU AU39910/95A patent/AU3991095A/en not_active Abandoned
- 1995-12-06 WO PCT/GB1995/002846 patent/WO1996017604A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989012627A1 (en) * | 1988-06-15 | 1989-12-28 | Brigham And Women's Hospital | S-nitroso derivatives of ace inhibitors and the use thereof |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
EP0441119A2 (en) * | 1990-01-09 | 1991-08-14 | Richard D. Levere | The use of L-Arginine in the treatment of hypertension and other vascular disorders |
WO1995002408A1 (en) * | 1993-07-16 | 1995-01-26 | Schering Aktiengesellschaft | Combination of a progestational agent and a nitric oxide synthase substrate and/or donor for the treatment of preeclampsia and preterm labor |
Non-Patent Citations (8)
Title |
---|
A. DE BELDER ET AL.: "TREATMENT OF HELLP SYNDROME WITH NITRIC OXIDE DONOR", THE LANCET, vol. 345, no. 8942, 14 January 1995 (1995-01-14), pages 124 - 125 * |
A.L.A. BOURA ET AL.: "AUTACOIDS AND CONTROL OF HUMAN PLACENTAL BLOOD FLOW", CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, vol. 21, pages 737 - 748 * |
B. RAMSAY ET AL.: "A NITRIC OXIDE DONOR IMPROVES UTERINE ARTERY DIASTOLIC BLOOD FLOW IN NORMAL EARLY PREGNANCY AND IN WOMEN AT HIGH RISK OF PRE-ECLAMPSIA", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 24, no. 1, pages 76 - 78 * |
C. YALLAMPALLI ET AL.: "INHIBITION OF NITRIC OXIDE SYNTHESIS IN RATS DURING PREGNANCY PRODUCES SIGNS SIMILAR TO THOSE OF PREECLAMPSIA", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 169, no. 5, pages 1316 - 1320 * |
D.B. COTTON ET AL.: "CARDIOVASCULAR ALTERATIONS IN SEVERE PREGNANCY-INDUCED HYPERTENSION: EFFECTS OF INTRAVENOUS NITROGLYCERIN COUPLED WITH BLOOD VOLUME EXPANSION", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 154, no. 5, pages 1053 - 1059 * |
E.J. LANGFORD ET AL.: "INHIBITION OF PLATELET ACTIVITY BY S-NITROSOGLUTATHIONE DURING CORONARY ANGIOPLASTY", THE LANCET, vol. 344, pages 1458 - 1460 * |
S.P. SELIGMAN ET AL.: "THE ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF PREECLAMPSIA", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 171, no. 4, pages 944 - 948 * |
W.R. KUKOVETZ ET AL.: "CELLULAR MECHANISMS OF ACTION OF THERAPEUTIC NITRIC OXIDE DONORS", EUROPEAN HERAT JOURNAL, vol. 12, pages 16 - 24 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627738B2 (en) | 1995-09-15 | 2003-09-30 | Duke University | No-modified hemoglobins and uses therefor |
US6916471B2 (en) | 1995-09-15 | 2005-07-12 | Duke University | Red blood cells loaded with S-nitrosothiol and uses therefor |
US6911427B1 (en) | 1995-09-15 | 2005-06-28 | Duke University | No-modified hemoglobins and uses therefore |
US6153186A (en) * | 1995-09-15 | 2000-11-28 | Duke University Medical Center | Red blood cells loaded with S-nitrosothiol and uses therefor |
US6197745B1 (en) | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
US6203789B1 (en) | 1995-09-15 | 2001-03-20 | Duke University | Red blood cells loaded with S-nitrosothiol and uses therefor |
US6884773B1 (en) | 1995-09-15 | 2005-04-26 | Duke University | Modified hemoglobins, including nitrosylhemoglobins, and uses thereof |
US6855691B1 (en) | 1995-09-15 | 2005-02-15 | Duke University | Methods for producing and using S-nitrosohemoglobins |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US6403759B2 (en) | 1996-08-02 | 2002-06-11 | Duke University | Polymers for delivering nitric oxide in vivo |
US6673891B2 (en) | 1996-08-02 | 2004-01-06 | Duke University | Polymers for delivering nitric oxide in vivo |
US7417109B2 (en) | 1996-08-02 | 2008-08-26 | Duke University | Polymers for delivering nitric oxide in vivo |
US6875840B2 (en) | 1996-08-02 | 2005-04-05 | Duke University | Polymers for delivering nitric oxide in vivo |
US7087709B2 (en) | 1996-08-02 | 2006-08-08 | Duke University | Polymers for delivering nitric oxide in vivo |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
WO1998009948A3 (en) * | 1996-09-04 | 1998-06-04 | Nicox Sa | Nitric ester derivatives and their use in urinary incontinence and other diseases |
WO1998009948A2 (en) * | 1996-09-04 | 1998-03-12 | Nicox S.A. | Nitric ester derivatives and their use in urinary incontinence and other diseases |
US6887994B2 (en) | 2000-10-26 | 2005-05-03 | Duke University | C-nitroso compounds and use thereof |
US7030238B2 (en) | 2000-10-26 | 2006-04-18 | Duke University | C-nitroso compounds and use thereof |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
WO2002034705A3 (en) * | 2000-10-26 | 2002-07-11 | Univ Duke | C-nitroso compounds and use thereof |
US7259250B2 (en) | 2000-10-26 | 2007-08-21 | Duke University | C-nitroso compounds and use thereof |
WO2002034705A2 (en) * | 2000-10-26 | 2002-05-02 | Duke University | C-nitroso compounds and use thereof |
US7785616B2 (en) | 2000-10-26 | 2010-08-31 | Duke University | C-nitroso compounds and use thereof |
Also Published As
Publication number | Publication date |
---|---|
GB9424694D0 (en) | 1995-02-01 |
AU3991095A (en) | 1996-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3665068B2 (en) | Combination of progesterone with nitric oxide synthase substrate and / or donor for the treatment of pre-eclampsia and preterm labor | |
US5973002A (en) | Prostaglandin E1 derivatives as pharmacologically active agents, especially for transcutaneous administration | |
US6054486A (en) | Use of 9-Deoxy-2',9-α-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen e)-13,14-dihydro-prostaglandin f1 to treat peripheral vascular disease | |
US8765813B2 (en) | Use of treprostinil to treat and prevent ischemic lesions | |
US4415554A (en) | Treatment for menstrual disorders | |
EP1696932B1 (en) | Use of treprostinil to improve kidney functions | |
Perera et al. | The relationship of sodium chloride to hypertension | |
WO1996017604A1 (en) | Use of a nitric oxide (no) donor for the treatment of hypertension during pregnancy | |
JP2001525803A (en) | Use of misoprostol and / or misoprostolic acid for the preparation of a medicament for the treatment of erectile dysfunction | |
US4322411A (en) | Anti-inflammatory nucleosides | |
EP0371789B1 (en) | Medicament for augmenting fetal hemoglobin | |
HU207220B (en) | Process for producing pharmaceutical composition for diminishing enhanced pressure of the pulmonary circulation | |
CA1327359C (en) | Prostaglandin el derivatives as pharmacologically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration | |
AU732532B2 (en) | Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor | |
JPH04501419A (en) | Treatment of hypertension | |
US3917864A (en) | Use of prostaglandins E and F for induction of labor | |
KR100907938B1 (en) | Use of alkanoyl L-carnitine for the treatment of erectile dysfunction | |
EP0309801B1 (en) | Use of thromboxane a2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction | |
IL117496A (en) | Nitric oxide donors and/or substrates and nitric oxide inhibitors for regulating cervical dilatation | |
US5192806A (en) | Method of preventing penile tissue degenerative change | |
JPH0136804B2 (en) | ||
JPH0445494B2 (en) | ||
WO1990003793A1 (en) | Compositions containing cyclosporins | |
Hui et al. | Potentiation of depressor responses to arachidonic acid by angiotensin converting enzyme inhibitors in the rat | |
Makkonen et al. | Myocardial infarction during pregnancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |